FDA Advisers Back Broader Humira Approval

Law360, New York (August 28, 2012, 6:45 PM EDT) -- A U.S. Food and Drug Administration advisory panel on Tuesday backed the use of Abbott Laboratories Inc.’s blockbuster anti-inflammatory drug Humira to treat the bowel disease ulcerative colitis, saying its benefits outweighed its risks, despite a recent FDA report questioning its efficacy in treating the condition.

The recommendation was passed along at a meeting of the FDA’s gastrointestinal drugs advisory committee, made up of a number of outside medical experts, which voted 15 to 2 that the expected benefits of Humira for certain patients with ulcerative...
To view the full article, register now.